Sensei Biotherapeutics, Inc. (SNSE): Price and Financial Metrics


Sensei Biotherapeutics, Inc. (SNSE): $1.39

-0.04 (-2.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SNSE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SNSE Stock Price Chart Interactive Chart >

Price chart for SNSE

SNSE Price/Volume Stats

Current price $1.39 52-week high $5.00
Prev. close $1.43 52-week low $1.30
Day low $1.36 Volume 35,478
Day high $1.46 Avg. volume 34,059
50-day MA $1.48 Dividend yield N/A
200-day MA $1.73 Market Cap 42.70M

Sensei Biotherapeutics, Inc. (SNSE) Company Bio


Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. The Company focuses in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics serves customers in the United States.


SNSE Latest News Stream


Event/Time News Detail
Loading, please wait...

SNSE Latest Social Stream


Loading social stream, please wait...

View Full SNSE Social Stream

Latest SNSE News From Around the Web

Below are the latest news stories about SENSEI BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate SNSE as an investment opportunity.

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo® (cemiplimab). The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors. Sensei is on track to

Yahoo | January 5, 2023

Sensei to shut Boston research site, cut workforce by ~40%

Sensei Biotherapeutics (SNSE) said it will close its research site in Boston and reduce its total workforce by ~40%.The company added that it will focus resources on its key…

Seeking Alpha | December 8, 2022

Immunotherapy startup shutters Boston research site, lays off 17

An immunotherapy startup that pulled off a $133 million IPO last year is shuttering its Boston research operations and laying off about 40% of its workforce.

Yahoo | December 8, 2022

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Sensei Biotherapeutics Inc (NASDAQ: SNSE) announced a streamlining and realignment of resources. The company will close its Boston research site and reduce its workforce by approximately 40% to extend Sensei's estimated cash runway into the second half of 2025 versus Q1 of 2025 expected earlier. The company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of its lead program SNS-101 and other TMAb programs is conducted while maintaining

Yahoo | December 8, 2022

Sensei Biotherapeutics Provides Update on Strategic Priorities

- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development of TMAb™ programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 -- Cash runway extended into the second half of 2025 -BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patient

Yahoo | December 8, 2022

Read More 'SNSE' Stories Here

SNSE Price Returns

1-mo -6.71%
3-mo 2.96%
6-mo -29.80%
1-year -71.16%
3-year N/A
5-year N/A
YTD -6.71%
2022 -74.31%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6425 seconds.